Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the new drug
ZARNESTRA (R115777) and temozolomide that can be given to patients with brain tumors
(glioblastoma multiforme, GBM). The second goal is to learn if these drugs given in
combination can shrink or slow the growth of brain tumors. The safety of this treatment will
also be studied.